HC Wainwright Brokers Lower Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA) – Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for shares of Humacyte in a report issued on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($1.36) per share for the year, down from their prior forecast of ($1.28). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Humacyte’s FY2025 earnings at ($0.77) EPS.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

HUMA has been the subject of a number of other reports. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. Finally, TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $11.00.

Humacyte Price Performance

Shares of HUMA stock opened at $4.84 on Friday. The company has a quick ratio of 5.41, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 12-month low of $2.35 and a 12-month high of $9.97. The firm has a fifty day moving average of $5.43 and a 200-day moving average of $6.16. The firm has a market capitalization of $577.06 million, a price-to-earnings ratio of -3.61 and a beta of 1.47.

Insider Buying and Selling

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares of the company’s stock, valued at $217,490.40. The trade was a 11.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Laura E. Niklason sold 157,704 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $5.42, for a total transaction of $854,755.68. Following the completion of the sale, the chief executive officer now owns 3,519,558 shares of the company’s stock, valued at approximately $19,076,004.36. This represents a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,084,153 shares of company stock worth $6,869,996. 11.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently bought and sold shares of the stock. Endowment Wealth Management Inc. lifted its holdings in Humacyte by 3.1% during the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after purchasing an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte during the second quarter worth $28,000. Private Advisor Group LLC boosted its position in shares of Humacyte by 1.8% in the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after acquiring an additional 6,510 shares during the period. The Manufacturers Life Insurance Company increased its position in Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after acquiring an additional 8,557 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.